Structure of neurotropic adeno-associated virus AAVrh.8
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Adeno-associated virus rhesus isolate 8 (AAVrh.8) is a leading vector for the treatment of neurological diseases due to its efficient transduction of neuronal cells and reduced peripheral tissue tropism. Toward identification of the capsid determinants for these properties, the structure of AAVrh.8 was determined by X-ray crystallography to 3.5 Å resolution and compared to those of other AAV isolates. The capsid viral protein (VP) structure consists of an αA helix and an eight-stranded anti-parallel β-barrel core conserved in parvoviruses, and large insertion loop regions between the β-strands form the capsid surface topology. The AAVrh.8 capsid exhibits the surface topology conserved in all AAVs: depressions at the icosahedral twofold axis and surrounding the cylindrical channel at the fivefold axis, and three protrusions around the threefold axis. A structural comparison to serotypes AAV2, AAV8, and AAV9, to which AAVrh.8 shares ~84, ~91, and ~87% VP sequence identity, respectively, revealed differences in the surface loops known to affect receptor binding, transduction efficiency, and antigenicity. Consistent with this observation, biochemical assays showed that AAVrh.8 is unable to bind heparin and does not cross-react with conformational monoclonal antibodies directed against the other AAVs compared. This structure of AAVrh.8 thus identified capsid surface differences which can serve as template regions for rational design of vectors with enhanced transduction for specific tissues and escape pre-existing antibody recognition. These features are essential for the creation of an AAV vector toolkit that is amenable to personalized disease treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864 · cited 1×
“…muscular dystrophy, hemophilia B, cystic fibrosis, Alzheimer’s disease, arthritis, lipoprotein lipase deficiency, Parkinson’s disease, and HIV infection (e.g. (Carter, 2006; Coura Rdos and Nardi, 2007; Daya and Berns, 2008; Mueller and Flotte, 2008; Nathwani et al., 2011; Stieger et al., 2011)).”
BackgroundIntravascular AAV9 preferentially targets neonatal neurons and adult astrocytes
Foust, K. D., Nurre, E., Montgomery, C. L., Hernandez, A., Chan, C. M., & Kaspar, B. K. (2009) · Nature Biotechnology · doi:10.1038/nbt.1515 · Cited by 1,456 · cited 8×
“D) from ideal bond lengths and angles were obtained from the CNS program (Brunger et al., 1998) and the average Bfactor for the VP3 model, solvent molecules, NT, and ions were calculated using the MOLEMAN program (Kleywegt and Jones, 1997).”
BackgroundInfluentialClades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues
Gao, G., Vandenberghe, L. H., Alvira, M. R., Lu, Y., Calcedo, R., Zhou, X., & Wilson, J. M. (2004) · Journal of Virology · doi:10.1128/jvi.78.12.6381-6388.2004 · Cited by 1,070
Self-citationBoutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M. F., & Masurier, C. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.182 · Cited by 970
Gene therapy using adeno-associated virus vectors
Daya, S., & Berns, K. I. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00008-08 · Cited by 926 · cited 1×
“…muscular dystrophy, hemophilia B, cystic fibrosis, Alzheimer’s disease, arthritis, lipoprotein lipase deficiency, Parkinson’s disease, and HIV infection (e.g. (Carter, 2006; Coura Rdos and Nardi, 2007; Daya and Berns, 2008; Mueller and Flotte, 2008; Nathwani et al., 2011; Stieger et al., 2011)).”
BackgroundTherapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges
Mingozzi, F., & High, K. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2988 · Cited by 893 · cited 1×
“…non-pathogenic parvovirus adeno-associated virus (AAV) show great promise as gene delivery vectors due to their ability to deliver packaged foreign genes for stable and long-term protein expression in a wide range of human tissues (reviewed in (Flotte and Carter, 1995; Mingozzi and High, 2011)).”
BackgroundThe atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy
Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., & Chapman, M. S. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162250899 · Cited by 612
Zhong, L., Li, B., Mah, C. S., Govindasamy, L., Agbandje-McKenna, M., Cooper, M., Herzog, R. W., Zolotukhin, I., Warrington, K. H., Weigel-Van Aken, K. A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802866105 · Cited by 558 · cited 4×
“AAV2 Y704 is also part of a series of tyrosines which when mutated to phenylalanines resulted in improved intracellular trafficking to the nucleus and hence increase in transduction efficiency dependent on the cell line (Zhong et al., 2008).”
BackgroundInfluentialSelf-citationDirected evolution of adeno-associated virus yields enhanced gene delivery vectors
Maheshri, N., Koerber, J. T., Kaspar, B. K., & Schaffer, D. V. (2006) · Nature Biotechnology · doi:10.1038/nbt1182 · Cited by 538 · cited 3×
“…Heparan sulfate receptor binding/Transduction (Kern et al., 2003; Opie et al., 2003; Summerford and Samulski, 1998); polyclonal neutralization (Maheshri et al., 2006); C37-B neutralization (Girod et al., 1999; Gurda et al., 2013; Huttner et al., 2003; Wobus et al., 2000); D3 neutralization…”
BackgroundGenetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2
Girod, A., Ried, M., Wobus, C., Lahm, H., Leike, K., Kleinschmidt, J., Deléage, G., & Hallek, M. (1999) · Nature Medicine · doi:10.1038/12491 · Cited by 405
Cited by
Adeno-Associated Virus (AAV) as a Vector for Gene Therapy
Naso, M. F., Tomkowicz, B., Perry, W. L., & Strohl, W. R. (2017) · BioDrugs · doi:10.1007/s40259-017-0234-5 · Cited by 1,362
Manufacturing challenges and rational formulation development for AAV viral vectors
Srivastava, A., Mallela, K. M. G., Deorkar, N., & Brophy, G. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2021.03.024 · Cited by 269
Capsid modifications for targeting and improving the efficacy of AAV vectors
Büning, H., & Srivastava, A. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.01.008 · Cited by 260
Twenty-Five Years of Structural Parvovirology
Mietzsch, M., Pénzes, J. J., & Agbandje-McKenna, M. (2019) · Viruses · doi:10.3390/v11040362 · Cited by 197
“To circumvent these inhibitory events, different strategies have been developed, including the utilization of immunosuppressants [130–133], the utilization of alternative natural AAV capsids that are not detected by the pre-existing human antibodies [68], the use of empty capsids as decoys [134], and the structure-gui…”
BackgroundMethodInfluentialSelf-citationUniversal Method for the Purification of Recombinant AAV Vectors of Differing Serotypes
Nass, S. A., Mattingly, M. A., Woodcock, D. A., Burnham, B. L., Ardinger, J. A., Osmond, S. E., Frederick, A. M., Scaria, A., Cheng, S. H., & O’Riordan, C. R. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.12.004 · Cited by 146
Understanding Capsid Assembly and Genome Packaging for Adeno-Associated Viruses
Bennett, A., Mietzsch, M., & Agbandje-McKenna, M. (2017) · Future Virology · doi:10.2217/fvl-2017-0011 · Cited by 82
Self-citationRationally designed AAV2 and AAVrh8R capsids provide improved transduction in the retina and brain
Sullivan, J. A., Stanek, L. M., Lukason, M. J., Bu, J., Osmond, S. R., Barry, E. A., O’Riordan, C. R., Shihabuddin, L. S., Cheng, S. H., & Scaria, A. (2018) · Gene Therapy · doi:10.1038/s41434-018-0017-8 · Cited by 37
Structure comparison of the chimeric AAV2.7m8 vector with parental AAV2
Bennett, A., Keravala, A., Makal, V., Kurian, J., Belbellaa, B., Aeran, R., Tseng, Y.-S., Sousa, D., Spear, J., Gasmi, M., et al. (2020) · Journal of Structural Biology · doi:10.1016/j.jsb.2019.107433 · Cited by 33
“Several AAV structures have been reported to contain nucleotide density in the capsid interior, referred to as the DNA binding pocket (Govindasamy et al., 2006; Halder et al., 2015; Lerch et al., 2010; Mikals et al., 2014; Nam et al., 2007; Ng et al., 2010).”
BackgroundSelf-citationAtomic structure of a rationally engineered gene delivery vector, AAV2. 5
Burg, M., Rosebrough, C., Drouin, L. M., Bennett, A., Mietzsch, M., Chipman, P., McKenna, R., Sousa, D., Potter, M., Byrne, B., et al. (2018) · Journal of Structural Biology · doi:10.1016/j.jsb.2018.05.004 · Cited by 30
Self-citationNovel AAV44.9-Based Vectors Display Exceptional Characteristics for Retinal Gene Therapy
Boye, S. L., Choudhury, S., Crosson, S., Di Pasquale, G., Afione, S., Mellen, R., Makal, V., Calabro, K. R., Fajardo, D., Peterson, J., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.04.002 · Cited by 29
“It was previously reported that AAVrh.8 transduced mouse inner retina following IVI.14 Our prior studies and those of others suggest that the ability of AAV to efficiently transduce retina following IVI is dependent on capsid binding to heparan sulfate proteoglycan (HSPG), a constitutive component of the inner limitin…”
BackgroundInfluentialGene therapy for the leukodystrophies: From preclinical animal studies to clinical trials.
Metovic, J., Li, Y., Gong, Y., & Eichler, F. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00443 · Cited by 16
“To evade pre-existing antibodies, the HEXA and HEXB transgenes were packaged into the neuro-tropic AAVrh.8 capsid [169,170].”
Background
Metadata
- Authors
- Halder, S., Van Vliet, K., Smith, J. K., Duong, T. T. P., McKenna, R., Wilson, J. M., & Agbandje-McKenna, M.
- Venue
- Journal of Structural Biology
- Publisher
- Elsevier BV
- Published
- 2015-10
- Volume
- 192
- Issue
- 1
- Pages
- 21-36
- ISSN
- 1047-8477 (ISSN-L)
- OpenAlex
- W1507799217
- Cited by
- 64
- References
- 42
- FWCI
- 3.29
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.